c Ceftolozane, formally CXA-101, is a new antipseudomonal cephalosporin that is also active in vitro against Enterobacteriaceae but is vulnerable to extended-spectrum ␤-lactamases (ESBLs). The addition of tazobactam is intended to broaden coverage to most ESBL-producing Escherichia coli and Klebsiella pneumonia as well as other Enterobacteriaceae. The in vitro activities of ceftolozane-tazobactam combinations against 67 clinically and molecularly characterized ESBL-producing isolates were examined by checkerboard MIC testing to evaluate their potential clinical feasibility and to assess the optimal tazobactam concentrations to be used in MIC determinations of ceftolozane. Isolates included those from E. coli (n ‫؍‬ 32), K. pneumoniae (n ‫؍‬ 19), Enterobacter cloacae (n ‫؍‬ 15), and Citrobacter freundii (n ‫؍‬ 1). Checkerboard experiments were performed to study interactions over the range of 0.008 to 64 mg/liter ceftolozane and 0.063 to 32 mg/liter tazobactam using 2-fold-dilution series. The T he global spread of extended-spectrum ␤-lactamases (ESBLs) has been an ongoing problem since the first report appeared in 1983 (1-3). Many 3rd-and 4th-generation cephalosporins are less effective in treating infections caused by these ESBL-producing isolates (4, 5). The development of new antibiotics has always played a key role in providing a solution to the emergence of these resistant mechanisms (6, 7). The new cephalosporin ceftolozane (CXA-101; Cubist Pharmaceuticals, Inc.) is a promising agent that possesses activity against Pseudomonas spp. and certain members of the Enterobacteriaceae family, but unfortunately the compound is still vulnerable to many ESBLs (8).
T
he global spread of extended-spectrum ␤-lactamases (ESBLs) has been an ongoing problem since the first report appeared in 1983 (1-3). Many 3rd-and 4th-generation cephalosporins are less effective in treating infections caused by these ESBL-producing isolates (4, 5) . The development of new antibiotics has always played a key role in providing a solution to the emergence of these resistant mechanisms (6, 7) . The new cephalosporin ceftolozane (CXA-101; Cubist Pharmaceuticals, Inc.) is a promising agent that possesses activity against Pseudomonas spp. and certain members of the Enterobacteriaceae family, but unfortunately the compound is still vulnerable to many ESBLs (8) .
Another approach to overcome resistance due to ␤-lactamases is to use a ␤-lactamase inhibitor in combination with a ␤-lactam antibiotic to extend its spectrum of activity. Currently available ␤-lactamase inhibitors include tazobactam, clavulanic acid, and sulbactam, and some bacteria grouped into Ambler class A and Class C may be inhibited by them (5, 9) . Existing drug combinations such as piperacillin-tazobactam and amoxicillin-clavulanic acid are still among the most successfully used antibiotics (10) .
Some in vitro studies (11) (12) (13) have previously indicated that combining ceftolozane with a ␤-lactamase inhibitor such as tazobactam might overcome its vulnerability to ESBLs. However, the optimal concentration of tazobactam to use in susceptibility testing is unclear, and the concentration-effect relationship against these isolates has yet to be established. Therefore, we set out to determine the inhibition of ESBL-producing isolates by ceftolozane and tazobactam using the checkerboard technique to examine the optimum concentration of tazobactam to enhance the MICs of ceftolozane.
MATERIALS AND METHODS
Bacterial isolates. We used 67 phenotypically and genotypically confirmed ESBL-producing isolates of Enterobacteriaceae that had been collected during a prevalence study. Details are described elsewhere (14) . The isolates included 32 Escherichia coli, 19 Klebsiella pneumoniae, 15 Enterobacter cloacae, and 1 Citrobacter freundii. In brief, initial screening for ESBL was done on BLSE agar biplates (AES Chemunex, Bruz Cedex, France). Presumptive ESBLs were confirmed by Etest TZ/TZL and CT/ CTL strips (AB Biodisk, Solna, Sweden) and, if necessary, the PM/PML strip. The modified Hodge test (MHT) was used to detect carbapenemase production when the MIC of meropenem was Ͼ0.125 mg/liter. PCR experiments were performed to detect bla TEM , bla SHV , bla OXA , and bla CTX-M genes. A summary of the ␤-lactamase characteristics of these isolates is shown in Table 1 .
Nine extra isolates producing K. pneumoniae carbapenemase (KPC) or AmpC enzymes, which did not or only poorly inhibited tazobactam (see the supplemental material), were added to serve as a negative control.
These included 6 K. pneumoniae isolates and 1 C. freundii isolate harboring KPC ␤-lactamase and 2 E. coli AmpC producers.
Compounds. Ceftolozane (lot 440420 00010) and tazobactam (lot 9080146JE) were provided as a standard powder by Cubist Pharmaceuticals, Inc. Ceftazidime was purchased commercially as ceftazidime pentahydrate (batch no. 18D3368). Stock solutions were prepared according to the manufacturer's instructions.
Susceptibility testing. MICs were determined by CLSI- (15) and ISOcompliant (16) methods for microbroth dilution. Working solutions of ceftolozane and tazobactam were made in freshly prepared Mueller-Hinton broth (MHB) (Difco batch no. 9106707; Brunschwig chemie, Amsterdam, Netherlands). Combinations of the two agents were used for the checkerboard titrations to yield a final range of log 2 dilutions of 0.008 to 64 mg/liter ceftolozane and 0.0625 to 32 mg/liter tazobactam, which encompassed the CLSI-approved concentration for tazobactam of 4 mg/ liter. Two disposable plastic microdilution trays were used for each determination with each tray containing a negative and a positive growth control, with every set of two containing 0.008 to 64 mg/liter ceftolozane alone and 0.008 to 64 mg/liter ceftazidime as a comparator as well. The trays were stored at Ϫ80°C until use. On the day of the experiment, trays were thawed, inoculated to a final concentration of 0.5 ϫ 10 5 CFU/ml, and incubated at 35°C in ambient air for 18 to 20 h. MICs were read with MIC being determined by the lowest concentration of the agent that completely inhibited visible growth. Each set of MIC determinations included three ATCC strains, E. coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), and K. pneumoniae (ATCC 700603), as controls.
Analysis. MIC 50 and MIC 90 values for ceftolozane, alone and combined with tazobactam, were defined as the lowest concentration of the antibiotic that inhibited 50% and 90% of the isolates of the collection, respectively.
The effect of tazobactam on the MIC of ceftolozane was expressed in the number of changes in 2-fold dilutions compared to the MIC of ceftolozane alone. The effect of the combination was depicted as the cumulative percentage (%) of isolates inhibited (Excel 2008 for Mac, version 12.3.6). The susceptibility to ceftazidime was interpreted according to EUCAST criteria (17) .
RESULTS
Ceftolozane alone showed a similar overall intrinsic activity against the 67 Enterobacteriaceae isolates compared to ceftazidime (see the supplemental material). The overall mean difference in MIC was 0.164 log 2 dilutions, which was not significantly different from 0. Overall, the MIC 50 and MIC 90 of ceftolozane alone were 16 and Ͼ64 mg/liter, respectively. The highest MICs were found among isolates harboring a CTX-M-15 enzyme with or without another ␤-lactamase. MICs of Ͼ64 mg/liter were found for 90% of the isolates carrying these genes for encoding CTX-M-15 enzymes.
Full ceftolozane-tazobactam checkerboard testing was performed for each isolate for all drug combinations stated. No change in MIC was observed after the addition of tazobactam for the isolates harboring KPC enzymes, and there was only a slight reduction in the MICs for the AmpC-producing isolates at very high concentrations. These isolates served as a negative control and were not taken into account while analyzing the study isolates.
The effects of tazobactam on the MICs of ceftolozane for the different species are shown in Fig. 1 as a cumulative inhibition in heat plots and as MIC 50 and MIC 90 values of ceftolozane for increasing concentrations of tazobactam (Table 2) . Each indicates a concentration-dependent effect of tazobactam on the in vitro activity of ceftolozane. As expected, tazobactam alone showed no effect (18) . The magnitude of the decrease in MIC was less for K. (Table 2 ). In contrast, MIC 50 values against K. pneumoniae showed a reasonable decline in MICs of ceftolozane although high MIC 90 values for K. pneumoniae persisted despite increasing tazobactam concentrations indicating that some isolates are not fully inhibited. Virtually no effect was observed for K. pneumoniae at tazobactam concentrations of Ͻ1 mg/liter, and at 4 mg/liter the MICs were still Ͼ8 mg/liter for 21% (n ϭ 4) of strains. Three of these isolates harbored SHV-5 enzymes suggesting that the efficacy of the ceftolozane-tazobactam combination also depends on the type of ESBL.
Tazobactam concentrations of Ͼ4 mg/liter did not markedly lower ceftolozane MICs further. At a fixed concentration of 4 mg/liter tazobactam, the MIC 50 and MIC 90 of ceftolozane were reduced to 0.5 and 4 mg/liter, respectively. A tazobactam concentration of 4 mg/liter resulted in an MIC for ceftolozane of Յ4 mg/liter for 90% of the total number of isolates, and adding more tazobactam did not result in a further reduction for 20% of the isolates.
At the highest tazobactam concentration tested (32 mg/liter), the median difference in 2-fold dilutions was 7 for E. coli, 6 for K. pneumoniae, and 4 for E. cloacae. The distribution of the changes in number of 2-fold dilutions compared to the initial MIC of ceftolozane without tazobactam is shown in Fig. 2 for concentrations of 1, 4, and 8 mg/liter tazobactam. For some isolates, a 10 log 2 decrease in MIC was observed, and there appears to be a bimodal distribution at 4 and 8 mg/liter tazobactam. The second subpopulation starting at 7 doubling dilutions consisted of E. coli isolates harboring at least a CTX-M-15 enzyme. MICs of ceftolozane against other species harboring this enzyme were less responsive by increasing tazobactam concentrations, indicating that the overall effect of the inhibitor is dependent on the species and type of enzyme. 
DISCUSSION
Our study showed that tazobactam enhanced the potency of ceftolozane against ESBL-producing Enterobacteriaceae in a dosedependent manner. However, the efficacy of this drug combination was also dependent on the species and type of ESBL. The most pronounced inhibitory effect was seen for E. coli. Combining ceftolozane with 4 mg/liter tazobactam restored 55% of the MICs to that reported for wild-type (non-ESBL) distributions (8, 19) .
The results show that increasing concentrations of tazobactam results in a decreased MIC of ceftolozane. With a fixed concentration of 4 mg/liter tazobactam, 90% of the isolates in this collection would have a combination MIC of Յ4 mg/liter (and an MIC 50 of 0.5 mg/liter), which extends the spectrum of activity of ceftolozane, thereby showing potential usefulness for treating infections due to ESBL-producing isolates. These results differ from those reported by Farrell et al. (20) and Sader et al. (12, 21) who conducted several large studies in Europe and the United States and used a collection of Enterobacteriaceae isolates with MIC 50 and MIC 90 values of 4 mg/liter and 32 mg/liter, which are higher than we found in our study. One explanation may be the higher resistance rate to piperacillin-tazobactam, ceftazidime, and meropenem in their studies. Unlike in our study, their isolates were ESBL screen-positive phenotypes based on the CLSI screening criteria for potential ESBL production and were not confirmed by other tests. Hence, no distinction was made between ESBLs and other ␤-lactamases such as KPC or AmpC that would also produce an ESBL screen-positive phenotype. We had no meropenemresistant isolates in our collection, and the ceftolozane MIC 50 was 4 mg/liter and the MIC 90 was 32 mg/liter when we recalculated the data with isolates exhibiting a piperacillin-tazobactam MIC of Ͼ16 mg/liter. This is similar to their findings. The same was observed for the ESBLs of E. coli isolates and, to a lesser extent, of K. pneumoniae isolates because they conferred a higher resistance to piperacillin-tazobactam and ceftazidime.
The number of isolates for each specific species-␤-lactamase combination was relatively small, and we cannot exclude the presence of additional resistant mechanisms or ESBLs that we were unable to detect. Nevertheless, since our study was representative of the isolates obtained from a prevalence survey, it provides a reasonable representation of the in vitro effects of tazobactam on the MIC of ceftolozane, as there is little or no bias in selecting the isolates. Moreover, the prevalence of CTX-M-15 concomitant with a TEM-1 and or an OXA-1 ␤-lactamase was consistent with observations in other European countries (22) (23) (24) .
A considerable number of isolates also exhibited multiple ␤-lactamases, and this is likely to increase over the next several years (25, 26) . The prevalence and distribution of specific ESBLs is often geographical and, therefore, monitoring trends in MICs will provide a valuable tool to combat ESBLs (27) . ␤-lactam-inhibitor combinations should also be tested specifically to determine whether shifts in prevalence or harboring multiple ESBLs have any impact on the MIC distributions. Using a concentration of 4 mg/liter tazobactam for such combinations in the microdilution assay seems a reasonable choice although the correlation between in vitro susceptibility test results and clinical efficacy should be demonstrated in pharmacodynamic studies in clinical studies.
In conclusion, ceftolozane in combination with 4 mg/liter tazobactam enhanced the overall in vitro activity against most of the Enterobacteriaceae harboring ESBLs. However, caution should be used for K. pneumoniae ESBLs, in particular SHV-5 and CTX-M-15, because high MICs remain despite by increasing tazobactam concentrations.
